UK markets open in 2 hours 30 minutes

Boston Scientific Corporation (BSX)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
41.32+1.50 (+3.77%)
At close: 04:00PM EDT
41.19 -0.13 (-0.31%)
After hours: 07:18PM EDT
Sign in to post a message.
  • D
    BUY BUY BUY ALOT MORE.......Good to Go

    Long Term BUY !!!!!!
  • D
    This was Good to BUY 2010.....2015.....2017.....2020

    And we are adding AGAIN......Prospects going forward keep

    getting BETTER!!!!!! Long Term Holder.......Lots of Luck !!!!!!
  • b
    Okay-finally see some movement. Up 4+%
  • b
    Folks-can we keep the dialogue specific to Boston Scientific and not about solicitations on stock trading websites?

    Muchas Gracias!
  • b
    I am convinced no matter how good the news might be no-one is buying it. Stock’s a dog!
  • L
    Why did this drop around 2004?
  • t
    BSX looks like it is about to drop. Be careful guys. I have been reading ( and their stocks have been doing way better.
  • T
    Boston in terrific! I want my fair share of it!
  • C
    On Friday someone purchased approximately 10,000 BSX April 14 $46 calls and sold the same amount of April 14 $37 puts. Their net cost was probably close to $0. This is pretty interesting, and it's bullish.
  • F
    $40 by the end of the year for sure. Mark my post.
  • D
    Bsx partnership with Nvcn or a buyout??
  • G
    Green Machine
    No big deal. Read that EPS will only be affected 1 to 2 cents in 2021. Great buy here! I just picked some up on the dip. Good luck all!
  • M
    I looked for a year to buy on today's price. One of the best companies in the market.
  • M
    Karen Firestone of Aureus Assets Management, #25 of Forbes Wealth Managers List, recommended Boston Scientific (BSX) as a top pick for 2021 on CNBC’s Halftime Report on 12/31/20. She views it as a Covid vaccine rebound play that has not yet caught up to an eventual post Covid reality. In 2020, she said, patients have delayed “elective” surgeries which will create a pent up demand for their cardiology devices.
  • c
    BSX target price increased to $40 from $32 at JPM........
  • A
    I hear 60 minutes is good show
  • J
    At least they are consistent with the earnings misses. Glad I sold at 37 yesterday - now I wonder what's the right re-entry point. Good thing is we are close to the floor at 34-35.
  • h
    Alright... Decided to jjjuurrrmpppp on in just below $25.
  • D
    Dickey Dukakis
    the broader market brought this down further today. however, revenue decline is a REAL concern here and will continue to be during COVID. being hyper-focused on efficiency is great, but the current market doesn't respect that nor care how many companies you acquired if they aren't bringing in revenue. Boston need to show real growth or tout the potential for growth to succeed in this difficult market. not to hate on this stock in particular, same is true for 90% of stocks out there. in 2 years, maybe Boston's acquisitions will pay off. CEO is strong. right now, what is their answer to corona though? when Medtronic got in on ventilators or
    3M upped their game in PPE, Boston just furloughed employees to save cash. okay, not the worst option but what happens next? convince me why I should touch any value stock right now when their are corona-proof growth stocks like ZOOM or Enphase? I revisit all med device companies once we have vaccines. until then, none of them are "safe" or winners until the market starts respecting value. also, a blue wave only hurts any med device company. in 2021, especially under full dem control, there will be very few stocks that win. don't make the mistake of listening to your financial advisor who pushes value stocks that will continue to lose until we see signs that these are starting to win.
  • R
    Here's the problem today:

    The awful part of this is that even if, as warned in this note, that the cause-and-effect has nothing to do with the coated devices, physicians are warned not to use them until the dust settles. So down we go. Why there's nothing about this in the financial press is very disappointing.
    Endovascular Today - FDA to Convene Advisory Committee Meeting After Preliminary Review Finds Signal of Increased Mortality With Paclitaxel-Eluting Devices